Aromatase Inhibitors: New Endocrine Treatment of Breast Cancer

Estrogens are involved in numerous physiological processes and have crucial roles in certain disease states such as mammary carcinoma. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is found in breast tissue, and the importance of intratumoral aromatase and local estrogen production is being unraveled. Inhibition of aromatase is an important approach for reducing growth stimulatory effects of estrogens in estrogen-dependent breast cancer. Competitive aromatase inhibitors are molecules that compete with the substrate androstenedione for noncovalent binding to the active site of the enzyme to decrease the amount of product formed. Steroidal inhibitors that have been developed to date build upon the basic androstenedione nucleus and incorporate chemical substituents at varying positions on the steroid. Nonsteroidal aromatase inhibitors can be divided into three classes: aminoglutethimide-like molecules, imidazole/triazole derivatives, and flavonoid analogs. Mechanism-based aromatase inhibitors are steroidal inhibitors that mimic the substrate, are converted by the enzyme to a reactive intermediate, and result in the inactivation of aromatase. Both steroidal and nonsteroidal aromatase inhibitors have shown clinical efficacy for the treatment of breast cancer. The initial nonselective nature of nonsteroidal inhibitor aminoglutethimide has been greatly reduced in the later generations of inhibitors, anastrozole and letrozole. Mechanism-based steroidal inhibitors such as 4-hydroxyandrostenedione and exemestane produce potent aromatase inhibition in patients. The potent and selective third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, are approved for clinical use in postmenopausal patients with advanced hormone-dependent breast cancer or in patients failing antiestrogen therapies. Several clinical studies of aromatase inhibitors are currently focusing on the use of these agents in the adjuvant setting for the treatment of early breast cancer.

KEYWORDS

Aromatase - steroidal inhibitors - nonsteroidal inhibitors - mechanism-based inhibitors - hormone-dependent breast cancer - adjuvant therapy

REFERENCES

• 1 Weigel N L, Rowan B G. Estrogen and progesterone action. In: DeGroot LJ, Jameson JL, Burger HG, et al. Endocrinology. Philadelphia; WB Saunders 2001: 2053-2060
• 2 Dickson R B, Lippman M E. Molecular basis of breast cancer. In: Mendelsohn J, Howley PH, Israel MA, Liotta LA The Molecular Basis of Cancer. Philadelphia; WB Saunders 1995: 358-386
• 3 Simpson E R, Mahendroo M S, Means G D, Kilgore M W, Corbin C J, Mendelson C R. Tissue-specific promoters regulate aromatase cytochrome P450 expression.  J Steroid Biochem Mol Biol. 1993;  44 321-330
• 4 James V H, McNeill J M, Lai L C, Newton C J, Ghilchik M W, Reed M J. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.  Steroids. 1987;  50 269-279
• 5 Miller W R, O'Neill J. The importance of local synthesis of estrogen within the breast.  Steroids. 1987;  50 537-548
• 6 Reed M J, Owen A M, Lai L C et al.. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.  Int J Cancer. 1989;  44 233-237
• 7 Reed M J. The role of aromatase in breast tumors.  Breast Cancer Res Treat. 1994;  30 7-17
• 8 Bulun S E, Price T M, Aitken J, Mahendroo M S, Simpson E R. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.  J Clin Endocrinol Metab. 1993;  77 1622-1628
• 9 Simpson E R, Mahendroo M S, Means G D et al.. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis.  Endocr Rev. 1994;  15 342-355
• 10 Kellis Jr J T, Vickery L E. Purification and characterization of human placental aromatase cytochrome P-450.  J Biol Chem. 1987;  262 4413-4420
• 11 Gartner C A, Thompson S J, Rettie A E, Nelson S D. Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry.  Protein Expr Purif. 2001;  22 443-454
• 12 Means G D, Kilgore M W, Mahendroo M S, Mendelson C R, Simpson E R. Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues.  Mol Endocrinol. 1991;  5 2005-2013
• 13 Simpson E R, Zhao Y, Agarwal V R et al.. Aromatase expression in health and disease.  Recent Prog Horm Res. 1997;  52 185-213
• 14 Simpson E R, Clyne C, Rubin G et al.. Aromatase: a brief overview.  Annu Rev Physiol. 2002;  64 93-127
• 15 Dowsett M, Macaulay V, Gledhill J et al.. Control of aromatase in breast cancer cells and its importance for tumor growth.  J Steroid Biochem Mol Biol. 1993;  44 605-609
• 16 Miller W R, Mullen P, Sourdaine P, Watson C, Dixon J M, Telford J. Regulation of aromatase activity within the breast.  J Steroid Biochem Mol Biol. 1997;  61 193-202
• 17 Reed M J, Topping L, Coldham N G, Purohit A, Ghilchik M W, James V H. Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors.  J Steroid Biochem Mol Biol. 1993;  44 589-596
• 18 Quinn A L, Burak Jr W E, Brueggemeier R W. Effects of matrix components on aromatase activity in breast stromal cells in culture.  J Steroid Biochem Mol Biol. 1999;  70 249-256
• 19 Aromatase 2000: Fifth International Aromatase Conference . J Steroid Biochem Mol Biol. 2001;  79 1-314 , 
• 20 Zhao Y, Agarwal V R, Mendelson C R, Simpson E R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene.  Endocrinology. 1996;  137 5739-5742
• 21 Zhou C, Zhou D, Esteban J et al.. Aromatase gene expression and its exon I usage in human breast tumors: detection of aromatase messenger RNA by reverse transcriptionpolymerase chain reaction.  J Steroid Biochem Mol Biol. 1996;  59 163-171
• 22 Hughes R, Timmermans P, Schrey M P. Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin-1beta and phorbol ester: dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function.  Int J Cancer. 1996;  67 684-689
• 23 Harris R E, Namboodiri K K, Farrar W B. Nonsteroidal antiinflammatory drugs and breast cancer.  Epidemiology. 1996;  7 203-205
• 24 Harris R E, Robertson F M, Abou-Issa H M, Farrar W B, Brueggemeier R. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.  Med Hypotheses. 1999;  52 291-292
• 25 Brueggemeier R W, Quinn A L, Parrett M L, Joarder F S, Harris R E, Robertson F M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.  Cancer Lett. 1999;  140 27-35
• 26 Richards J A, Brueggemeier R W. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.  J Clin Endocrinol Metab. 2003;  88 2810-2816
• 27 Carmichael P L. Mechanisms of action of antiestrogens: relevance to clinical benefits and risks.  Cancer Invest. 1998;  16 604-611
• 28 Jordan V C. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer.  Annu Rev Pharmacol Toxicol. 1995;  35 195-211
• 29 Harvey H A, Lipton A, Santen R J. Aromatase: new perspectives for breast cancer.  Cancer Res. 1982;  42 3261s-3467s
• 30 Santen R J. Aromatase conference: future perspectives. Steroids 1987 50: 1-665
• 31 Brodie A M, Brodie H J, Callard G, Robinson C H, Roselli C, Santen R J. Proceedings of the Third International Aromatase Conference.  J Steroid Biochem Mol Biol. 1993;  44 321-696
• 32 Simpson E R, Bhatnagar A, Brodie A M et al.. Proceedings of the Fourth International Aromatase Conference.  J Steroid Biochem Mol Biol. 1997;  61 107-425
• 33 Johnston J O, Metcalf B W. Aromatase: a target enzyme in breast cancer. In: Sunkara P Novel Approaches to Cancer Chemotherapy. New York; Academic 1984: 307-328
• 34 Banting L, Smith H J, James M et al.. Structure-activity relationships for non-steroidal inhibitors of aromatase.  J Enzyme Inhib. 1988;  2 215-229
• 35 Banting L, Nicholls P J, Shaw M A, Smith H J. Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer.  Prog Med Chem. 1989;  26 253-298
• 36 Covey D F. Aromatase inhibitors: specific inhibitors of oestrogen biosynthesis. In: Berg D, Plempel M Sterol Biosynthesis Inhibitors. Chichester, UK; Ellis Horwood 1988: 534-571
• 37 Brueggemeier R W. Biochemical and molecular aspects of aromatase.  J Enzyme Inhib. 1990;  4 101-111
• 38 Brueggemeier R W. Aromatase inhibitors: mechanisms of steroidal inhibitors.  Breast Cancer Res Treat. 1994;  30 31-42
• 39 Cole P A, Robinson C H. Mechanism and inhibition of cytochrome P-450 aromatase.  J Med Chem. 1990;  33 2933-2942
• 40 Brodie A M, Njar V C. Aromatase inhibitors and breast cancer.  Semin Oncol. 1996;  23 10-20
• 41 Brodie A, Lu Q, Long B. Aromatase and its inhibitors.  J Steroid Biochem Mol Biol. 1999;  69 205-210
• 42 Santen R J, Harvey H A. Use of aromatase inhibitors in breast carcinoma.  Endocr Relat Cancer. 1999;  6 75-92
• 43 Schwarzel W C, Kruggel W G, Brodie H J. Studies on the mechanism of estrogen biosynthesis, VIII: The development of inhibitors of the enzyme system in human placenta.  Endocrinology. 1973;  92 866-880
• 44 Siiteri P K, Thompson E A. Studies of human placental aromatase.  J Steroid Biochem. 1975;  6 317-322
• 45 Brueggemeier R W, Floyd E E, Counsell R E. Synthesis and biochemical evaluation of inhibitors of estrogen biosynthesis.  J Med Chem. 1978;  21 1007-1011
• 46 Brueggemeier R W, Katlic N E. Effects of the aromatase inhibitor 7 alpha-(4′-amino)phenylthio-4-androstene-3,17-dione in MCF-7 human mammary carcinoma cell culture.  Cancer Res. 1987;  47 4548-4551
• 47 Brueggemeier R W, Katlic N E, Kenreigh C A, Li P K. Aromatase inhibition by 7-substituted steroids in human choriocarcinoma cell culture.  J Steroid Biochem Mol Biol. 1992;  41 85-90
• 48 Brueggemeier R W, Li P K. Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.  Cancer Res. 1988;  48 6808-6810
• 49 Kellis J T, Childers W E, Robinson C H, Vickery L E. Inhibition of aromatase cytochrome P-450 by 10-oxirane and 10-thiirane substituted androgens: implications for the structure of the active site.  J Biol Chem. 1987;  262 4421-4426
• 50 Childers W E, Shih M J, Furth P S, Robinson C H. Stereoselective inhibition of human placental aromatase.  Steroids. 1987;  50 121-134
• 51 Shih M J, Carrell M H, Carrell H L, Wright C L, Johnston J O, Robinson C H. Stereoselective inhibition of aromatase by novel epoxysteroids.  J Chem Soc Chem Comm. 1987;  213-214
• 52 Bednarski P J, Porubek D J, Nelson S D. Thiol-containing androgens as suicide substrates of aromatase.  J Med Chem. 1985;  28 775-779
• 53 Wright J N, Calder M R, Akhtar M. Steroidal C-19 sulfur and nitrogen derivatives designed as aromatase inhibitors.  J Chem Soc Chem Comm. 1985;  1733-1735
• 54 Peet N P, Burkhart J P, Wright C L, Johnston J O. Time-dependent inhibition of human placental aromatase with a 2,19-methyleneoxy-bridged androstenedione.  J Med Chem. 1992;  35 3303-3306
• 55 Peet N P, Johnston J O, Burkhart J P, Wright C L. A-ring bridged steroids as potent inhibitors of aromatase.  J Steroid Biochem Mol Biol. 1993;  44 409-420
• 56 Johnston J O, Wright C L, Burkhart J P, Peet N P. Biological characterization of A-ring steroids.  J Steroid Biochem Mol Biol. 1993;  44 623-631
• 57 Metcalf B W, Wright C L, Burkhart J P, Johnston J O. Substrate-induced inactivation of aromatase by allenic and acetylenic steroids.  J Am Chem Soc. 1981;  103 3221-3222
• 58 Covey D F, Hood W F, Parikh V D. 10 beta-propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of estrogen biosynthesis.  J Biol Chem. 1981;  256 1076-1079
• 59 Marcotte P A, Robinson C H. Synthesis and evaluation of 10 beta-substituted 4-estrene-3, 17-diones as inhibitors of human placental microsomal aromatase.  Steroids. 1982;  39 325-344
• 60 Johnston J O, Wright C L, Metcalf B W. Biochemical and endocrine properties of a mechanism-based inhibitor of aromatase.  Endocrinology. 1984;  115 776-785
• 61 Johnston J O, Wright C L, Metcalf B W. Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture.  J Steroid Biochem. 1984;  20 1221-1226
• 62 Longcope C, Femino A, Johnston J O. Inhibition of peripheral aromatization in baboons by an enzyme-activated aromatase inhibitor (MDL 18,962).  Endocrinology. 1988;  122 2007-2011
• 63 Johnston J O. Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase.  Steroids. 1987;  50 105-120
• 64 Brodie A M, Garrett W M, Hendrickson J R, Tsai-Morris C H, Marcotte P A, Robinson C H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo.  Steroids. 1981;  38 693-702
• 65 Brodie A M, Schwarzel W C, Shaikh A A, Brodie H J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.  Endocrinology. 1977;  100 1684-1695
• 66 Wing L Y, Garrett W M, Brodie A M. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.  Cancer Res. 1985;  45 2425-2428
• 67 Brodie A M, Brodie H J, Garrett W M, Hendrickson J R, Marsh D A, Tsai-Morris C H. Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo.  Biochem Pharmacol. 1982;  31 2017-2023
• 68 Coombes R C, Goss P, Dowsett M, Gazet J C, Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.  Lancet. 1984;  2 1237-1239
• 69 Goss P E, Powles T J, Dowsett M, Hutchison G, Brodie A M. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.  Cancer Res. 1986;  46 4823-4826
• 70 Dowsett M. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.  Ann Oncol. 1994;  5 S3-S5
• 71 Goss P E, Jarman M, Wilkinson J R, Coombes R C. Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.  J Steroid Biochem. 1986;  24 619-622
• 72 Wiseman L R, Goa K L. Formestane: a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.  Drugs Aging. 1996;  9 292-306
• 73 Covey D F, Hood W F. Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity.  Endocrinology. 1981;  108 1597-1599
• 74 Covey D F, Hood W F. Aromatase enzyme catalysis is involved in the potent inhibition of estrogen biosynthesis caused by 4-ace.  Mol Pharmacol. 1982;  21 173-180
• 75 Snider C E, Brueggemeier R W. Potent enzyme-activated inhibition of aromatase by a 7 alpha-substituted C19 steroid.  J Biol Chem. 1987;  262 8685-8689
• 76 Li P K, Brueggemeier R W. 7-substituted steroidal aromatase inhibitors: structure-activity relationships and molecular modeling.  J Enzyme Inhib. 1990;  4 113-120
• 77 Ebrahimian S, Chen H H, Brueggemeier R W. Synthesis and biochemical studies of 7 alpha-substituted androsta-1,4-diene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase.  Steroids. 1993;  58 414-422
• 78 O'Reilly J M, Brueggemeier R W. 7alpha-Arylaliphatic androsta-1,4-diene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase.  J Steroid Biochem Mol Biol. 1996;  59 93-102
• 79 Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, Di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.  J Steroid Biochem. 1988;  30 391-394
• 80 Zaccheo T, Giudici D, Lombardi P, Di Salle E. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.  Cancer Chemother Pharmacol. 1989;  23 47-50
• 81 Zaccheo T, Giudici D, Di Salle E. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats.  J Steroid Biochem Mol Biol. 1993;  44 677-680
• 82 Di Salle E, Giudici D, Briatico G, Ornati G. Novel irreversible aromatase inhibitors.  Ann N Y Acad Sci. 1990;  595 357-367
• 83 Cocconi G. First generation aromatase inhibitors-aminoglutethimide and testololactone.  Breast Cancer Res Treat. 1994;  30 57-80
• 84 Hoffken K. Experience with aromatase inhibitors in the treatment of advanced breast cancer.  Cancer Treat Rev. 1993;  19(suppl B) 37-44
• 85 Weber M M, Will A, Adelmann B, Engelhardt D. Effect of ketoconazole on human ovarian C17,20-desmolase and aromatase.  J Steroid Biochem Mol Biol. 1991;  38 213-218
• 86 Bhatnagar A S, Hausler A, Schieweck K, Browne L J, Bowman R, Steele R E. Novel aromatase inhibitors.  J Steroid Biochem Mol Biol. 1990;  37 363-367
• 87 Furet P, Batzl C, Bhatnagar A, Francotte E, Rihs G, Lang M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.  J Med Chem. 1993;  36 1393-1400
• 88 Vanden Bossche H, Willemsens G, Roels I et al.. R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis.  Biochem Pharmacol. 1990;  40 1707-1718
• 89 Wouters W, Snoeck E, De Coster R. Vorozole, a specific non-steroidal aromatase inhibitor.  Breast Cancer Res Treat. 1994;  30 89-94
• 90 Plourde P V, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor.  Breast Cancer Res Treat. 1994;  30 103-111
• 91 Bhatnagar A S, Hausler A, Schieweck K, Lang M, Bowman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.  J Steroid Biochem Mol Biol. 1990;  37 1021-1027
• 92 Demers L M. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.  Breast Cancer Res Treat. 1994;  30 95-102
• 93 Adlercreutz H, Bannwart C, Wahala K et al.. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens.  J Steroid Biochem Mol Biol. 1993;  44 147-153
• 94 Wang C, Makela T, Hase T, Adlercreutz H, Kurzer M S. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes.  J Steroid Biochem Mol Biol. 1994;  50 205-212
• 95 Kellis Jr J T, Vickery L E. Inhibition of human estrogen synthetase (aromatase) by flavones.  Science. 1984;  225 1032-1034
• 96 Ibrahim A R, Abul-Hajj Y J. Aromatase inhibition by flavonoids.  J Steroid Biochem Mol Biol. 1990;  37 257-260
• 97 Le Bail J C, Laroche T, Marre-Fournier F, Habrioux G. Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids.  Cancer Lett. 1998;  133 101-106
• 98 Le Bail J C, Pouget C, Fagnere C, Basly J P, Chulia A J, Habrioux G. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities.  Life Sci. 2001;  68 751-761
• 99 Kao Y C, Zhou C, Sherman M, Laughton C A, Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study.  Environ Health Perspect. 1998;  106 85-92
• 100 Pouget C, Fagnere C, Basly J P et al.. Synthesis and aromatase inhibitory activity of flavanones.  Pharm Res. 2002;  19 286-291
• 101 Pouget C, Fagnere C, Basly J P, Habrioux G, Chulia A J. Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition.  Bioorg Med Chem Lett. 2002;  12 2859-2861
• 102 Recanatini M, Bisi A, Cavalli A et al.. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.  J Med Chem. 2001;  44 672-680
• 103 Brueggemeier R W, Richards J A, Joomprabutra S, Bhat A S, Whetstone J L. Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents.  J Steroid Biochem Mol Biol. 2001;  79 75-84
• 104 Lipton A, Santen R J. Proceedings: medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.  Cancer. 1974;  33 503-512
• 105 Santen R J, Samojlik E, Lipton A et al.. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.  Cancer. 1977;  39 2948-2958
• 106 Santen R J, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women.  Endocr Rev. 1990;  11 221-265
• 107 Brodie A M. Aromatase inhibitors in the treatment of breast cancer.  J Steroid Biochem Mol Biol. 1994;  49 281-287
• 108 Goss P E, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer.  J Clin Oncol. 2001;  19 881-894
• 109 Ingle J N. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.  Oncology (Huntingt). 2001;  15 28-34
• 110 Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.  Clin Cancer Res. 2001;  7 2620-2635
• 111 Murray R. Role of anti-aromatase agents in postmenopausal advanced breast cancer.  Cancer Chemother Pharmacol. 2001;  48 259-265
• 112 Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.  Oncology (Huntingt). 2001;  15 965-972
• 113 Geisler J, King N, Dowsett M et al.. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in postmenopausal women with breast cancer.  Br J Cancer. 1996;  74 1286-1291
• 114 Jonat W, Howell A, Blomqvist C et al.. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.  Eur J Cancer. 1996;  32A 404-412
• 115 Buzdar A U, Jones S E, Vogel C L, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.  Cancer. 1997;  79 730-739
• 116 Buzdar A, Jonat W, Howell A et al.. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.  J Clin Oncol. 1996;  14 2000-2011
• 117 Bonneterre J, Thurlimann B, Robertson J F et al.. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.  J Clin Oncol. 2000;  18 3748-3757
• 118 Nabholtz J M, Buzdar A, Pollak M et al.. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.  J Clin Oncol. 2000;  18 3758-3767
• 119 Bonneterre J, Buzdar A, Nabholtz J M et al.. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.  Cancer. 2001;  92 2247-2258
• 120 Geisler J, Haynes B, Anker G, Dowsett M, Lonning P E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.  J Clin Oncol. 2002;  20 751-757
• 121 Dowsett M, Jones A, Johnston S R, Jacobs S, Trunet P, Smith I E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.  Clin Cancer Res. 1995;  1 1511-1515
• 122 Dombernowsky P, Smith I, Falkson G et al.. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.  J Clin Oncol. 1998;  16 453-461
• 123 Buzdar A, Douma J, Davidson N et al.. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.  J Clin Oncol. 2001;  19 3357-3366
• 124 Mouridsen H, Gershanovich M, Sun Y et al.. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.  J Clin Oncol. 2001;  19 2596-2606
• 125 Evans T R, Di Salle E, Ornati G et al.. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.  Cancer Res. 1992;  52 5933-5939
• 126 Bajetta E, Zilembo N, Noberasco C et al.. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.  Eur J Cancer. 1997;  33 587-591
• 127 Geisler J, King N, Anker G et al.. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.  Clin Cancer Res. 1998;  4 2089-2093
• 128 Lonning P E, Bajetta E, Murray R et al.. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.  J Clin Oncol. 2000;  18 2234-2244
• 129 Lonning P E. Pharmacology and clinical experience with exemestane.  Expert Opin Investig Drugs. 2000;  9 1897-1905
• 130 Miller W R, Dixon J M. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.  Cancer Control. 2002;  9 9-15
• 131 Brueggemeier R W, Katlic N E. Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures.  Cancer Res. 1990;  50 3652-3656
• 132 Yue W, Brodie A M. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.  J Steroid Biochem Mol Biol. 1997;  63 317-328
• 133 Soudon J. Comparison of in vitro exemestane activity versus other antiaromatase agents.  Clin Breast Cancer. 2000;  1 S68-S73
• 134 Miller W R, Dixon J M. Antiaromatase agents: preclinical data and neoadjuvant therapy.  Clin Breast Cancer. 2000;  1 S9-S14
• 135 Ingle J N. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.  Oncology (Huntingt). 2001;  15 28-34
• 136 Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.  Clin Cancer Res. 2001;  7 2620-2635
• 137 Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women.  Breast Cancer Res Treat. 2001;  69 210
• 138 Ellis M J, Jaenicke F, llombart-Cussac A et al.. Letrozole (Femara) is a more effective anti-proliferative agent than tamoxifen irrespective of ErbB1 and/or ErbB2 positive status: evidence from a phase III randomized trial of neoadjuvant endocrine therapy for postmenopausal women with estrogen receptor positive primary breast cancer.  Breast Cancer Res Treat. 2001;  69 211
• 139 Moon R C, Steele V E, Kelloff G J et al.. Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone.  Anticancer Res. 1994;  14 889-893
• 140 De Coster R, Van Ginckel R F, Callens M J, Goeminne N K, Janssens B L. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.  Cancer Res. 1992;  52 1240-1244
• 141 Lubet R A, Steele V E, Casebolt T L, Eto I, Kelloff G J, Grubbs C J. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.  Carcinogenesis. 1994;  15 2775-2780
• 142 Schieweck K, Bhatnagar A S, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.  J Steroid Biochem Mol Biol. 1993;  44 633-636